BOSTON SCIENTIFIC BUYS LEADERSHIP POSITION IN INTERVENTIONAL NEURORADIOLOGY WITH $1.1 BIL. TARGET MERGER; STOCK DEAL RESOLVES COMPANIES' PATENT DISPUTE
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's $1.1 bil. merger agreement with Target Therapeutics puts the interventional neuroradiology segment firmly in the hands of large, diversified medical products firms.
You may also be interested in...
Essure Permanent Birth Control Will Become Standard Of Care – Conceptus
Conceptus expects its Essure non-incisional permanent birth control device to replace tubal ligation for the estimated 700,000 women undergoing sterilization procedures in the U.S. annually
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.